Skip to main content
. Author manuscript; available in PMC: 2022 Dec 9.
Published in final edited form as: J Invest Dermatol. 2018 Jul 19;138(12):2531–2539. doi: 10.1016/j.jid.2018.06.186

Figure 2. HSP70iQ435A can drive repigmentation of vitiligo lesions in Sinclair swine.

Figure 2.

(a) An example (DNA-treated) vitiligo lesion that has developed around a melanoma tumor is followed over time using a lasso and image analysis to quantify the area of depigmentation (outer margins shown). (b) significant repigmentation is observed in seven vitiligo lesions treated with HSP70iQ435A- encoding DNA, as well as seven distant lesions, each compared to five PBS-treated lesions from separate swine (slopes −12.5, −14.2, and +31.9, respectively; P < 0.0001 for both comparisons). The straight lines display the slopes calculated from the underlying data, which are shown as the mean change in lesional area at each time point. (c) Represented as repigmentation in percentage increments, repigmentation was observed in the majority of treated and distant lesions whereas vehicle treated lesions primarily depigmented over time. HSP70iQ435A, inducible HSP70Q435A; PBS, phosphate buffered saline.